The results from the phase I portion of a phase I/II dose-escalation study of glufosfamide in combination with gemcitabine, marketed by Eli Lilly under the brand name Gemzar, have shown glufosfamide to be well-tolerated and to warrant further investigation.
“Based on these encouraging results, we have progressed to the phase II portion of this study to assess the potential for glufosfamide combined with gemcitabine to treat patients with pancreatic cancer who have not previously received chemotherapy,” said Alan Colowick, Threshold’s chief medical officer.
The phase II portion of the study will investigate the efficacy of glufosfamide in combination with gemcitabine as determined by response rate, duration of response, progression-free survival, overall survival, six and twelve month survival and change in serum tumor marker levels.